jcm-logo

Journal Browser

Journal Browser

Current Clinical Advances in Urinary Incontinence

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 357

Special Issue Editors


E-Mail Website
Guest Editor
1. Division of Gynecology and Obstetrics, University Clinical Center Ljubljana, 1000 Ljubljana, Slovenia;
2. Department of Gynecology and Obstetrics, Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
Interests: urinary incontinence; prolapse; pelvic floor dysfunction; reconstructive surgery; laser treatment

E-Mail
Guest Editor
1. Division of Gynecology and Obstetrics, University Clinical Center Ljubljana, 1000 Ljubljana, Slovenia;
2. Department of Gynecology and Obstetrics, Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
Interests: urinary incontinence; pelvic floor dysfuntion; surgery; energy based devices; conservative treatment

E-Mail Website
Guest Editor
1. Division of Gynecology and Obstetrics, University Clinical Center Ljubljana, 1000 Ljubljana, Slovenia;
2. Department of Gynecology and Obstetrics, Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
Interests: urinary incontinence; pelvic organ prolapse; pelvic floor dysfuntion; pelvic reconstructive and gynecological surgery; tissue engineering

Special Issue Information

Dear Colleagues,

Urinary incontinence (UI) is a highly prevalent condition on a global scale, causing a significant impact on patients' quality of life and a considerable economic burden on healthcare systems. It is estimated that more than half of women aged 60 years or older suffer from stress urinary incontinence (SUI). Overactive bladder (OAB) syndrome, whether idiopathic or neurogenic, is another chronic condition associated with urgency incontinence, affecting both genders and negatively impacting multiple aspects of daily life. As UI is an age-related condition, its prevalence is expected to rise significantly in the coming decades.

The management of UI has evolved considerably, offering a broad spectrum of treatment options ranging from conservative and minimally invasive therapies to advanced surgical techniques. First-line conservative treatments, including PFMT, biofeedback, neuromodulation, behavioral therapy, and pharmacological interventions, play a crucial role in the management of symptoms and may prevent the progression of incontinence, especially in its early stages. Additionally, new technologies such as MS and non-surgical energy-based devices are emerging as promising, non-invasive alternatives for patients who are either unfit for surgery or unwilling to undergo it.

Despite the extensive range of available treatments, there is no universal "perfect" therapy for UI. While mid-urethral slings (MUSs) have long been a mainstay of surgical treatment for female SUI, their use has been restricted or abandoned in some countries due to complication risks. This has further reinforced the need to explore safer, less invasive alternatives.

Our aim in launching this Special Issue is to gather high-quality contributions focusing on the latest and most innovative advances in the physiopathology, diagnosis, conservative and surgical management, and prevention of UI. We invite the submission of research articles and comprehensive reviews exploring the following topics:

  • Emerging diagnostic technologies for a more precise evaluation of UI;
  • Advances in conservative therapies, including PFMT, pharmacotherapy, and non-invasive devices;
  • Surgical innovations and minimally invasive procedures for UI management;
  • The impact of UI on quality of life and strategies for patient-centered care.

All researchers are invited to contribute original works and systematic reviews.

Prof. Dr. Adolf Lukanovic
Dr. David Lukanović
Dr. Mija Blaganje
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • female urinary incontinence
  • stress urinary incontinence
  • overactive bladder
  • diagnosis
  • prevention
  • conservative treatment
  • minimally invasive treatment
  • surgery
  • mid-urethral sling
  • new approach
  • energy-based devices

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 199 KiB  
Article
An Investigation of the Effect of Combining Tolterodine and Duloxetine in the Treatment of Mixed-Type Urinary Incontinence and the Factors Affecting Success
by Resul Sobay and Eyüp Veli Küçük
J. Clin. Med. 2025, 14(10), 3575; https://doi.org/10.3390/jcm14103575 - 20 May 2025
Viewed by 267
Abstract
Background: Mixed urinary incontinence (MUI), particularly the urge-predominant subtype, involves both stress urinary incontinence (SUI) and urge urinary incontinence (UUI), posing a therapeutic challenge. Duloxetine, a serotonin–norepinephrine reuptake inhibitor (SNRI), enhances urethral tone, while tolterodine, an antimuscarinic agent, reduces detrusor overactivity. Their [...] Read more.
Background: Mixed urinary incontinence (MUI), particularly the urge-predominant subtype, involves both stress urinary incontinence (SUI) and urge urinary incontinence (UUI), posing a therapeutic challenge. Duloxetine, a serotonin–norepinephrine reuptake inhibitor (SNRI), enhances urethral tone, while tolterodine, an antimuscarinic agent, reduces detrusor overactivity. Their combination may offer synergistic benefits. Aim: The aim of this study was to evaluate the efficacy of duloxetine and tolterodine combination therapy in urge-predominant MUI and identify factors influencing treatment success. Method: A retrospective study was conducted on 106 patients (mean age: 56.45 years) with urge-predominant MUI treated with duloxetine (40 mg twice daily) and tolterodine (4 mg once daily) for 12 weeks. Treatment outcomes were evaluated using the overactive bladder symptom score (OABSS), International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), 24 h pad test, and Clinical Global Impression Scale (CGI). Univariate and multivariate regression analyses were performed to determine predictors of success. Results: Significant improvements were observed: OABSS decreased from 11.08 to 6.95, ICIQ-SF decreased from 15.69 to 8.84, and pad use decreased from 3.58 to 0.73/day (all p 0.0001). Bladder capacity increased from 315.09 mL to 436.32 mL. Baseline ICIQ-SF scores were independent predictors of success (odds ratio [OR] = 2.919, p = 0.001). Patient satisfaction reached 77.4%, with mild side effects (constipation and dizziness) in 14 patients. Conclusions: Duloxetine and tolterodine combination therapy significantly improved symptoms and quality of life in urge-predominant MUI. Baseline ICIQ-SF scores may predict treatment success. Further prospective studies are needed. Full article
(This article belongs to the Special Issue Current Clinical Advances in Urinary Incontinence)
Back to TopTop